CoChat

Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy

Open access
Landen, Jaren W., Cohen, Sharon, Billing, Clare B., Cronenberger, Carol, Styren, Scot, Burstein, Aaron H., Sattler, Catherine, Lee, Jae‐Hong, Jack, Clifford R., Kantarci, Kejal, Schwartz, Pamela F., Duggan, William T., Zhao, Qinying, Sprenger, Ken, Bednar, Martin M., Binneman, Brendon · 2017 · Alzheimer's & Dementia: Translational Research & Clinical Interventions
Cited by 64

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Introduction: Multiple intravenous doses of ponezumab, an anti‐amyloid antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's disease (AD). Methods: In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed for 6 months thereafter. Results: Ponezumab was generally safe and well tolerated. Most common adverse events were fall (16.7% ponezumab, 21.4% placebo), headache (13.8%, 21.4%), and cerebral microhemorrhage (13.8%, 19.6%). Plasma ponezumab increased dose‐dependently with limited accumulation. Cerebrospinal fluid penetration was low. Plasma Aβ 1–x and Aβ 1–40 showed robust increases, but cerebrospinal fluid biomarkers showed no dose response. Ponezumab had no effects on cognitive/functional outcomes or brain volume. Conclusions: Multiple‐dose ponezumab was generally safe, but not efficacious, in mild‐to‐moderate AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trci.2017.04.003

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 64

Metadata

Authors
Landen, J. W., Cohen, S., Billing, C. B., Cronenberger, C., Styren, S., Burstein, A. H., Sattler, C., Lee, J., Jack, C. R., Kantarci, K., Schwartz, P. F., Duggan, W. T., Zhao, Q., Sprenger, K., Bednar, M. M., & Binneman, B.
Venue
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher
Wiley
Published
2017-05-10
Volume
3
Issue
3
Pages
339-347
ISSN
2352-8737 (ISSN-L)
OpenAlex
W2613104019
Cited by
64
References
3
FWCI
3.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy. https://app.cochat.ai/papers/10.1016/j.trci.2017.04.003
The paper
Landen, J. W., Cohen, S., Billing, C. B., Cronenberger, C., Styren, S., Burstein, A. H., Sattler, C., Lee, J., Jack, C. R., Kantarci, K., Schwartz, P. F., Duggan, W. T., Zhao, Q., Sprenger, K., Bednar, M. M., & Binneman, B. (2017). Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1016/j.trci.2017.04.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.